Active surveillance vs surgery for low-risk prostate cancer

Research-informed explainer — last updated April 12, 2026

For men diagnosed with low-risk, localized prostate cancer, the first decision is often the hardest: treat now with surgery (or radiation), or monitor closely and delay treatment unless the cancer shows signs of growing. Two decades of randomized trial data now support both paths as reasonable, with the key trade-off landing not on survival — which is similar — but on quality of life and the side effects each approach carries.

This explainer compares active surveillance and radical prostatectomy for low-risk disease. It draws on research from urologists in the Convene directory, including investigators from the PIVOT trial and specialists at UCSF, Harvard, and UCLA.

What's the difference?

Active surveillance means monitoring the cancer closely rather than treating it immediately. Typical protocols include regular PSA blood tests every three to six months, periodic prostate biopsies, and sometimes MRI scans. Treatment is started only if the cancer shows signs of progressing — a rise in grade, an increase in the volume of cancer found on biopsy, or a pattern of PSA change that suggests growth. The cancer stays in your body, but so does the possibility that it never needs to be treated.

Radical prostatectomy is the surgical removal of the prostate gland, either by open surgery or, more commonly now, by robotic-assisted laparoscopy. It removes the cancer along with the prostate. The main risks are urinary incontinence and erectile dysfunction, both of which are common to varying degrees in the months after surgery. Recovery takes several weeks, and the functional side effects can be permanent in some men.

The comparison matters most for low-risk disease — tumors that are Gleason grade group 1 (Gleason score 6), confined to the prostate, and with a PSA below 10. For higher-risk disease, the case for treatment is stronger, and the comparison shifts accordingly.

At a glance

What the PIVOT trial showed

The most direct evidence comes from the PIVOT trial (Prostate Intervention Versus Observation Trial), a randomized study of 731 men with localized prostate cancer. At 12 years of follow-up, published in the New England Journal of Medicine in 2012, prostatectomy did not significantly reduce all-cause or prostate-cancer mortality compared with observation — with absolute differences in mortality under three percentage points [1].

The 20-year PIVOT follow-up, published in 2017, held to the same conclusion: surgery was not associated with significantly lower mortality than observation. Surgery was associated with more adverse events but with less frequent treatment for disease progression, mostly for biochemical recurrence rather than life-threatening spread [2]. This long follow-up is important because prostate cancer often moves slowly — short-term data can favor one approach simply because the disease hasn't had time to declare itself.

These findings apply most squarely to men with low- to intermediate-risk disease. PIVOT enrolled a broad mix of patients, and the subgroup with low PSA and low-grade cancer showed the least benefit from surgery. The subgroup with higher PSA (above 10 ng/mL) showed a trend toward benefit with surgery, which is part of why risk stratification matters so much for this decision.

The overtreatment problem

Research examining national treatment patterns using the CaPSURE registry, one of the largest prostate cancer observational databases in the country, found that in a cohort of nearly 12,000 men, practice location explained 13 to 74 percent of the variation in which treatment was chosen — far more than patient characteristics or tumor features [4]. That kind of variation is a warning sign for treatment decisions driven by habit or institutional culture rather than patient-specific risk.

A review in European Urology on overdiagnosis and overtreatment laid out the core problem: PSA screening has identified large numbers of cancers that would never have caused symptoms or death if left untreated, and for many years the default response was surgery or radiation [3]. Active surveillance was developed specifically to give men with low-risk cancer a way to avoid those side effects unless the cancer actually progresses.

Risk assessment tools

The decision between surveillance and surgery isn't made in a vacuum — it depends on how risky the cancer actually looks. The UCSF Cancer of the Prostate Risk Assessment (CAPRA) score uses PSA level, Gleason grade, clinical stage, percent of biopsy cores positive, and age to generate a risk score from 0 to 10. It was developed and validated in a UCSF cohort and has since been validated externally as a reliable predictor of disease recurrence after prostatectomy [5]. Scores of 0 to 2 correspond to the low-risk category where active surveillance is most appropriate.

Side effects of surgery: what the data show

Urinary incontinence is the most common functional side effect of prostatectomy. A systematic review and meta-analysis of outcomes after robot-assisted radical prostatectomy tracked recovery rates across studies. The data showed that continence recovery takes time — most men recover within 12 months — but rates of persistent incontinence vary substantially by surgeon volume and center experience [6].

Erectile dysfunction is the other major concern. Nerve-sparing techniques have improved outcomes, but a meaningful proportion of men experience long-term changes in sexual function regardless of technique. These side effects are rarely reversible, and their impact on quality of life can be significant — particularly for men in their 50s or 60s with low-risk disease who may not have needed treatment at all.

When surgery is more clearly the right call

For higher-risk prostate cancer, the calculus changes. For Gleason score 9-10 disease, a JAMA study comparing radical prostatectomy, external beam radiation, and radiation with brachytherapy boost showed that the combination radiation approach was associated with better cancer-specific mortality and longer time to distant metastasis [7]. Active surveillance is not appropriate for high-grade disease.

Younger men with longer life expectancy, men with higher-volume low-risk disease (more cores positive on biopsy), and men who experience significant anxiety living with an unremoved cancer are also reasonable candidates for treatment over surveillance.

Questions to ask your doctor

• What is my CAPRA score or D'Amico risk group, and what does that mean for my surveillance vs. treatment decision?
• If I choose active surveillance, what triggers would lead you to recommend starting treatment?
• How many robotic prostatectomies does your center perform per year, and what are your reported rates of continence and erectile function recovery?
• What are the surveillance protocols — how often do I need PSA tests, biopsies, and MRIs?
• How long can I safely wait before I need to decide?
• Given my age and overall health, which path are you seeing patients like me choose, and why?

The bottom line

For men with low-risk, localized prostate cancer, active surveillance and radical prostatectomy lead to similar survival outcomes based on the best available randomized evidence. The difference is in what happens along the way. Surgery removes the cancer now but carries real risks of incontinence and erectile dysfunction. Surveillance avoids those side effects but requires ongoing monitoring and living with the possibility of future treatment. The right choice depends on the specific features of your cancer, your age and health, and your tolerance for uncertainty. Both options deserve a full conversation with an experienced urologist before deciding.